What is IMVT-1402 (imeroprubart), and is it approved?

IMVT-1402, now named imeroprubart, is Immunovant's investigational antibody that blocks FcRn, the receptor that recycles IgG antibodies, so disease-causing autoantibodies are cleared faster. It is not FDA approved. Myasthenia gravis: a potentially registrational Phase 3 trial in generalized myasthenia gravis (NCT07039916), with topline data expected in 2027. Graves' disease: trials Immunovant describes as Phase 2b in Graves' disease (NCT06727604 and NCT07018323), with topline data expected in 2027. CIDP and Sjögren's: Phase 2b trials in CIDP (NCT07032662) and Sjögren's disease, with data expected in 2028. Rheumatoid arthritis: a potentially registrational trial in difficult-to-treat rheumatoid arthritis. Source: Immunovant, August 6, 2026 and the Immunovant pipeline.

What happened to Immunovant's batoclimab?

Both Phase 3 trials of batoclimab in thyroid eye disease missed their main goal, a proptosis response of 2mm or more at week 24, Immunovant reported on April 2, 2026. Next: Immunovant said it would review batoclimab's future with its partner HanAll, and by August 2026 it described its batoclimab trials as winding down. Its work now centers on IMVT-1402. Source: Immunovant, April 2, 2026 and Immunovant, August 6, 2026.

What rare diseases does Immunovant, Inc. focus on?

Immunovant, Inc. has active programs across 4 rare diseases: Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, Myasthenia Gravis, Sjögren's Syndrome. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

How can I find Immunovant, Inc. clinical trials for rare diseases?

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Immunovant, Inc., pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

How do I enroll in an Immunovant, Inc. clinical trial?

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

What FDA-approved rare disease drugs does Immunovant, Inc. have?

None as of November 2026. Immunovant, Inc. has no FDA-approved drug yet; its programs are still in trials. Most advanced: Imeroprubart (Phase 3). Where to watch: the FDA calendar lists any Immunovant, Inc. application once a decision date is public, and the trials list on this page shows what is recruiting now.

Immunovant, Inc.

Drugmaker with rare disease work · part of Roivant · based in Durham, United States · ticker IMVT · immunovant.com

Immunovant, Inc. works on 4 rare diseases we track, including Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease and 2 more. It has 3 active clinical trials, and 2 are looking for volunteers now.

Immunovant is a drug company based in Durham, North Carolina, and a majority-owned subsidiary of Roivant. It is developing IMVT-1402 (imeroprubart), an antibody that blocks FcRn, the receptor that recycles IgG antibodies, so disease-causing autoantibodies are cleared faster.

Immunovant, Inc. pipeline

Each row lists the diseases Immunovant, Inc. is studying at that stage, from the ones closest to approval down to the earliest work.

Phase 3

Large studies, usually the last step before a company asks the FDA for approval.

Myasthenia Gravis recruiting

Phase 2

Mid-size studies that check whether a drug works and at what dose.

Chronic Inflammatory Demyelinating Polyneuropathy recruiting · Sjögren's Syndrome

Immunovant, Inc. clinical trials

These are Immunovant, Inc. trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.

2 trials looking for volunteers now

Looking for volunteersPhase 2Recently updatedNCT07032662

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Tests Imeroprubart, Placebo

For Chronic Inflammatory Demyelinating Polyneuropathy

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

Ages 18 Years+142 locations

View full study

Looking for volunteersPhase 3Updated a few months agoNCT07039916

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Tests IMVT-1402, IMVT-1402, Placebo, IMVT-1402

For Generalized Myasthenia Gravis

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Ages 18 Years - 80 Years88 locations

View full study

1 trial underway, not taking new volunteers

Underway, not taking new volunteersPhase 2Recently updatedNCT06979531

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Tests IMVT-1402, Placebo

For Primary Sjögren's Syndrome

This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).

Ages 18 Years - 74 Years96 locations

View full study

Ask about Immunovant, Inc.'s trials

Answers with sources, in plain English

Start withor ask

Follow a condition Immunovant, Inc. is studying

Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Immunovant, Inc.. Unsubscribe anytime.

Condition to follow

You'll get, for Chronic Inflammatory Demyelinating Polyneuropathy:

Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month

Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

More about Immunovant, Inc.

IMVT-1402 is in a potentially registrational trial in myasthenia gravis and in Graves' disease trials, with topline data expected in 2027, and in trials in CIDP and Sjögren's disease, with data expected in 2028. It has no FDA-approved drug. Its earlier FcRn antibody, batoclimab, missed its main goal in 2 Phase 3 thyroid eye disease trials in April 2026, and Immunovant is winding down the batoclimab trials.

Where Immunovant, Inc. trials take place

The trials above run at 326 study sites in 34 countries. Tap a country to see its states, cities and hospitals.

United States

110▼

Poland

33▼

Italy

20▼

Argentina

16▼

Germany

16▼

Spain

14▼

Greece

13▼

United Kingdom

12▼

Hungary

10▼

Brazil

8▼

Chile

8▼

Romania

7▼

Rare diseases Immunovant, Inc. works on

Each disease page lists every open trial, not only Immunovant, Inc.'s, plus approved treatments.

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder affecting the peripheral nerves, causing progressive weakness and impaired function in the legs and arms.

How common: About 2.8 per 100,000 people in a 2019 pooled analysis of 9 studies (Broers et al., Neuroepidemiology); NORD estimates 5 to 7 per 100,000, and NIH's GARD estimates about 50,000 people in the U.S

Graves’ Disease

Graves' disease is the most common cause of hyperthyroidism, an autoimmune condition where antibodies stimulate the thyroid gland to produce excessive thyroid hormone.

How common: Affects about 1 in 200 people; most common in women ages 30-50

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue.

How common: 1 in 5,000 people

Sjögren's Syndrome

Sjögren's syndrome is a chronic autoimmune disorder in which the immune system attacks the moisture-producing exocrine glands, primarily the salivary and lacrimal (tear) glands.

How common: Estimated 1 to 4 million Americans (including undiagnosed); approximately 1 in 1,000 adults based on physician-diagnosed prevalence

Where to get support

Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Immunovant, Inc.'s own site is immunovant.com, and our help paying for treatment page lists drugmaker programs and charity funds.

GBS|CIDP Foundation International
Chronic Inflammatory Demyelinating Polyneuropathy
NORD - Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
American Thyroid Association
Graves’ Disease
Graves' Disease & Thyroid Foundation
Graves’ Disease
Myasthenia Gravis Foundation of America (MGFA)
Myasthenia Gravis
NIH GARD - Myasthenia Gravis
Myasthenia Gravis
Sjögren's Foundation
Sjögren's Syndrome
NORD - Sjögren Syndrome
Sjögren's Syndrome

Immunovant, Inc.

Immunovant, Inc. pipeline

Immunovant, Inc. clinical trials

2 trials looking for volunteers now

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

1 trial underway, not taking new volunteers

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

More about Immunovant, Inc.

Where Immunovant, Inc. trials take place

Rare diseases Immunovant, Inc. works on

Where to get support

Other companies working on the same diseases

Questions about Immunovant, Inc.